About: Innate Immunotherapeutics

Innate Immunotherapeutics (INNM) was a biopharmaceutical company, previously known as Virionyx, with headquarters in Sydney, Australia and a branch in Auckland, New Zealand. Their focus in 2009 was the "development of a new generation of immune response modifier for potential use in the treatment of a range of infectious diseases, certain cancers, and as a novel cellular and humoral adjuvant, " and developed a proprietary multiple sclerosis drug, MIS416. In April 2009 the firm changed its name to Innate Immunotherapeutics to reflect their focus on the development of MIS416, and moved their headquarters from Auckland, New Zealand to Sydney, Australia. On June 22, 2017, Innate Immunotherapeutics announced that the MIS416 clinical trials undertaken to evaluate its efficacy in managing seconda